Verastem, Inc.
Verastem, Inc. (VSTM) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Needham, United States and has 102 employees. The company is worth $911.07M. Revenue was $30.91M in fiscal 2025, up 209.1% from the year before. It reported a net loss of $209.47M. The share price is 7.0% below its 52-week high of $10.82. 4 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Israel Englander (Millennium Management), at $7.94M. In that quarter, 1 of them opened or added to the position and 3 reduced it. Over the last 30 days, company insiders sold $373.5K of its stock on the open market and bought none.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -73.0% over 5Y.
today you would have $277.24▼ -72.3%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 14 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $7.72 | $5.17 | $8.14 | $4.80 | $24.60 | $25.56 | $16.08 | $40.32 | $36.84 | $13.44 | $22.32 | $109.68 | $136.80 | $105.48 | |
| P/S | 21.9x | 21.9x | 26.6x | — | 30.9x | 186.1x |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| RIGLRigel Pharmaceuticals Inc | $48.86 | 2.9x | 2.1x | 0.00% | 126.90% | $912.7M |
| BVSBioventus Inc. | $13.30 | 17.1x | 4.0x | 0.00% | 25.68% | $908.46M |
| SVRASavara Inc | $4.45 | — | 7.9x | 0.00% | -105.48% | $914.3M |
| CGEMCullinan Therapeutics, Inc. | $14.92 |
| 4.1x |
| 11.4x |
| 9.3x |
| — |
| — |
| — |
| — |
| — |
| — |
| P/B | 2.7x | 11.9x | — | 3.6x | 1.7x | 4.4x | 3.2x | 27.7x | 2.0x | 2.7x | 0.6x | 0.7x | 3.7x | 2.5x | 2.1x |
| EPS | -$3.02 | -$3.66 | -$3.96 | -$4.57 | -$4.90 | -$5.28 | -$24.00 | -$16.44 | -$21.12 | -$11.88 | -$19.32 | -$24.84 | -$21.84 | -$20.40 |
| Profit margin | -854.77% | -677.59% | -1306.37% | — | -2843.30% | -3468.10% | -76.51% | -854.77% | -271.11% | — | — | — | — | — | — |
| ROE | -60.12% | -366.23% | — | -152.28% | -155.75% | -81.32% | -58.75% | -2079.86% | -58.27% | -117.54% | -50.40% | -56.47% | -60.12% | -35.08% | -35.35% |
Median of the years shown; P/E years above 200x are left out.
| — |
| 3.0x |
| 0.00% |
| -50.30% |
| $916.95M |
| QDELQuidelOrtho Corp | $13.48 | — | 0.5x | 0.00% | -45.91% | $924.4M |
| CRVSCorvus Pharmaceuticals, Inc. | $10.65 | — | 4.0x | 0.00% | -35.43% | $895.89M |